Abstract Library

#4654 Usefulness of soluble tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors R2 and R3 in progression assessment of gastroenteropancreatic neuroendocrine neoplasms – A preliminary study

Introduction: TRAIL is a member of TNF family and appears in membrane and soluble (s) forms. It acts either triggering (R1 and R2) or blocking (R3 and R4) apoptosis. TRAIL targeted therapy is widely studied and known as potentially effective in number of neoplasms.

Conference:

Presenting Author: Kaczmarska-Turek D

Authors: Kaczmarska-Turek D, Radziszewski M, Matałowski M, Liszcz A, Bartoszewicz Z,

Keywords: gastroenteropancreatic neuroendocrine neoplasm, tumour necrosis factor-related apoptosis-inducing ligand, tumour progression, PRRT, TRAIL, GEP-NEN,

#4652 Clinical response to somatostatin analogues in patients with DIPNECH: Findings from a new longitudinal registry

Introduction: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) often presents with symptoms of cough and dyspnoea. DIPNECH remains understudied, and response to somatostatin analogues (SSAs) has been reported in a few small series.

Conference:

Presenting Author: Libre M

Authors: Libre M, Skotte E, Linden A, Wu J, Lippincott E,

Keywords: DIPNECH, somatostatin analogue,

#4477 Stable tumoural response to stereotactic body radiotherapy in well-differentiated metastatic small intestine neuroendocrine tumour

Introduction: Over half of patients with Neuroendocrine tumours (NET) have unresectable or metastatic disease. SSA y PRRT are successful targeted therapy to symptoms relief and stabilise disease. Otherwise, there are emerging options of radiotherapy including hypofractionation or stereotactic body radiotherapy. The clinical evidence of radiotherapy in NEN is scarce, and there is limited published data.

Conference:

Presenting Author: Florez A

Authors: Sanabria D, Florez A,

Keywords: Neuroendocrine, Tumour, metastatic,

#4448 Statins and somatostatin analogues in gastroenteropancreatic neuroendocrine tumours (GEP-NET): Impact on overall survival

Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP-NET) are rare neoplasia with unclear risk factor influencing their development and survival. Statins appear to enhance antiproliferative effect of some chemotherapies in other cancers, but their effect in GEP-NET treated with somatostatin analogues (SSA) are largely unknown.

Conference:

Presenting Author: Benevento E

Authors: Benevento E, Liccardi A, Minotta R, Cannavale G, Di Iasi G,

Keywords: statins, neuroendocrine tumour, gastroenteropancreatic, overall survival, somatostatin analogue,

#4402 Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomised study of cessation of somatostatin analogues after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumours

Introduction: After progressing on somatostatin analogues (SSA), patients with somatostatin receptor positive gastroenteropancreatic (GEP) NETs often receive PRRT. It is unclear whether current practice of continuing SSA after commencing PRRT is beneficial, especially in non-functioning NETs.

Conference:

Presenting Author:

Authors: Burge M, Wyld D, Pattison D, Loree J, Goodwin R,

Keywords: Somatostatin analogue, peptide receptor radionuclide therapy, gastroenteropancreatic, neuroendocrine, non-functioning, cessation, Australasian Gastro-Intestinal Trials Group (AGITG), Canadian Cancer Trials Group (CCTG),